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Abstract
Background: Expression of the oestrogen receptor (ER) in breast cancer predicts benefit from endocrine therapy.
Minimising the frequency of false negative ER status classification is essential to identify all patients with ER positive breast
cancers who should be offered endocrine therapies in order to improve clinical outcome. In routine oncological practice ER
status is determined by semi-quantitative methods such as immunohistochemistry (IHC) or other immunoassays in which
the ER expression level is compared to an empirical threshold[1,2]. The clinical relevance of gene expression-based ER
subtypes as compared to IHC-based determination has not been systematically evaluated. Here we attempt to reduce the
frequency of false negative ER status classification using two gene expression approaches and compare these methods to
IHC based ER status in terms of predictive and prognostic concordance with clinical outcome.
Methodology/Principal Findings: Firstly, ER status was discriminated by fitting the bimodal expression of ESR1 to a mixed
Gaussian model. The discriminative power of ESR1 suggested bimodal expression as an efficient way to stratify breast
cancer; therefore we identified a set of genes whose expression was both strongly bimodal, mimicking ESR expression
status, and highly expressed in breast epithelial cell lines, to derive a 23-gene ER expression signature-based classifier. We
assessed our classifiers in seven published breast cancer cohorts by comparing the gene expression-based ER status to IHC-
based ER status as a predictor of clinical outcome in both untreated and tamoxifen treated cohorts. In untreated breast
cancer cohorts, the 23 gene signature-based ER status provided significantly improved prognostic power compared to IHC-
based ER status (P=0.006). In tamoxifen-treated cohorts, the 23 gene ER expression signature predicted clinical outcome
(HR=2.20, P=0.00035). These complementary ER signature-based strategies estimated that between 15.1% and 21.8%
patients of IHC-based negative ER status would be classified with ER positive breast cancer.
Conclusion/Significance: Expression-based ER status classification may complement IHC to minimise false negative ER
status classification and optimise patient stratification for endocrine therapies.
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Introduction
Breast cancer is classified into clinically relevant subtypes based
on the expression of the oestrogen receptor (ER), classifying
tumours into ER positive and ER negative cases. These subtypes
are characterized by fundamentally different clinical risk for
disease-specific survival and response to various therapies[3]. ER
positive tumours are generally associated with better prognosis
than ER negative tumours and respond well to endocrine
therapies affecting oestrogen receptor activity. On the other hand,
ER negative tumours are highly proliferative and insensitive to
endocrine therapies. Consequently, the correct classification of ER
status, with particular attention to minimising the false negative
rate, has far reaching clinical implications in prognostication and
patient stratification for treatment. In current clinical practice, ER
expression levels are measured by semi-quantitative methods such
as immunohistochemistry (IHC) or enzymatic immunoassay (EIA).
To determine the ER status of a given tumour, an empirical,
subjectively chosen threshold has to be set. There are major
drawbacks of such a method; firstly, the analytical set-up is difficult
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protocols such as the length of antigen retrieval and tissue fixation
differ from centre to centre resulting in a significant level of
variation in ER status classification[4]; thirdly, the ER status
derived from immunostaining approaches remains a subjective
judgement[5]; finally, the relationship between the empirical
threshold of ER positivity and the true underlying biological
function of the receptor, which is likely to determine endocrine
therapy sensitivity, is poorly elucidated[4]. These factors together
may result in a significant level of discordance of ER status
classification with a major impact on treatment choice and clinical
outcome in breast cancer.
Clinical studies of breast cancer have suggested that microarray-
based gene expression profiling may serve as a robust alternative to
immunohistochemistry to determine ER status in breast can-
cer[5,6,7,8]. Furthermore, the abundance of genes quantified by
high throughput profiling has led to the discovery of a complex
molecular network regulated by ER[9]. However, determination
of the optimal threshold for gene expression-based ER predictors
still remains problematic. One approach is to compare microarray
based expression measurements of the ER to those of IHC and
define the threshold value as the probe level that best separates ER
positive from ER negative tumours, determined according to
conventional methodologies[5]. Another approach is to select
genes highly correlated with ESR1 and define molecular subtypes
corresponding to pathological ER status based on the bimodal
distribution of the expression levels of a selected gene set[10,11].
These expression-based methods yield generally consistent
classifications in most of the samples tested between selected
ESR1 probe levels and the corresponding ER expression
measured by IHC. However, the concordance of the two methods
varies from one data set to another. Indeed, for a significant
proportion of samples, gene expression based classification and
IHC based classification differ, and it is currently unclear whether
these cases behave clinically more like true ER positive or true ER
negative cases[5]. Furthermore, both methods may produce false
predictions due to experimental deficiencies: for IHC-based
classification, false negatives may arise from experimental or
subjective errors detailed above. In fact it is possible that the
observed discordance between ER status calls in primary and
recurrent breast cancer is in some cases due to errors in IHC based
classification rather than a reflection of a true change in tumour
biology[12]. Direct comparison of the two methods reveals
discrepancies but does not establish which method is more
accurate.
We have chosen to investigate whether ER status defined by
gene expression-based approaches or IHC produces more
homogeneous patient cohorts in terms of clinical behaviour and
outcome. We focus on clinical outcome in patients treated with
and without endocrine therapy with discrepant ER classification in
order to estimate and define the potential impact of false negative
ER classification status on prognosis.
Materials and Methods
This study was conducted in compliance to Dana Farber/
Harvard Cancer Center, Institutional Review Board, protocol 93-
085 with appropriated patient consent.
Expression data sets and clinical annotation
For derivation of the genes specifically expressed in epithelium,
we performed gene-expression profile analysis in breast cancer cell
lines and sorted tumour epithelial cells. The data is publicly
available from ‘‘Gene Expression Omnibus’’ (GEO) with accession
number GSE23640 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE23640).
For meta-analyses, we chose ten data sets with pathological
annotation of ER status based on IHC, EIA or both, incorporating
a total of 1975 breast cancer specimens to derive and validate the
classifiers for ER status (Table 1). These data sets were from
independent studies and all publicly available[8,10,13–20].
Redundant samples were excluded according to the annotated
sample origins.
Weused the DFCIdata setsasthereference data forderivation of
both expression-based ER classifiers. For the meta-analysis and
Kaplan-Meier survival curves, we used selected samples from six
validation sets (EMC, JBI1, GIS, NKI, TAM and VDX)
[8,15,16,18,21,22], of which both the treatment and follow-up data
were available from the original studies. The survival analyses were
performed separately for patients received systematic treatment and
patients did not.
Table 1. Summary of breast cancer cohorts used in this study.
Number of
patients
ER positive
tumors (%)
Experiments for
detecting ER expression
Received hormone/
adjuvant therapy (%)
Follow-up time
Median (range) in years
DFCI 175 100 (57.14) IHC NA NA
MSK 99 57 (57.58) IHC NA NA
EMC 286 209 (73.08) 10%, IHC;
10 fmol/mg, EIA
0 (0) 7.17 (0.17–14.25)
JBI1 189 149 (78.84) IHC 64 (33.86) 6.02 (0.02–14.53)
JBI2 120 0 (0) IHC 120 (100.00) NA
GIS 289 211 (73.01) 0.05 fmol/mg, EIA 147 (50.87) 9.92 (0–12.75)
JBI3 198 134 (67.68) IHC 198 (100.00) 12.50 (0.40–24.95)
MDA1 133 82 (61.65) 10%, IHC 133 (100.00) NA
MDA/MAQC 100 61 (61.00) 10%, IHC 100 (100.00) NA
NKI 295 226 (76.61) 10%, IHC 130 (44.07) 7.22 (0.05–18.34)
TAM 155 155 (100%) IHC 155 (100.00) 5.32 (0.12–13.76)
VDX 136 136 (100%) IHC 136 (100.00) 6.98 (0.63–15.83)
doi:10.1371/journal.pone.0015031.t001
A 23 Gene Expression Signature of ER Status
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e15031ER classification based on mixed Gaussian model
We used the Affymetrix HGU133a/HGU133plus2 probe set
‘‘205225_at’’ to represent the expression level of ESR1. We first
verified the bimodal distribution using coefficient of bimodality
with a threshold of 0.555. Then we decomposed the bimodal
distribution into two Gaussian distributions, which correspond to
two specific ER expression statuses. Based on the two inferred
distributions we derived a cohort-specific cut-off value for ESR1
using Mahalanobis distance which minimizes the estimated false
positive rate (FPR) and the false negative rate (FNR).
ER classification based on gene expression signature
In order to derive a multi-gene expression signature for ER
status, we collected nine cell lines (mostly ER negative) and five
primary tumours samples enriched for epithelial cells by digesting
tissue and sorting cells using BerEp4 antibody coated beads and
profiled mRNA expression using microarray[23]. Next we selected
17256 genes which were classified as ‘‘present calls’’ in more than
50% of the samples by ‘‘dChip’’ [24]. In order to exclude possible
confounding effects, we removed a further 1142 genes which are
highly expressed in stromal tissue from laser-capture microdis-
sected data sets using mix-effects linear model. From the
remaining genes we selected 258 genes of which the coefficient
of bimodality was larger than 0.555. Finally we selected 23 genes
of which the estimated false positive and false negative rates of
discrimination were both below 0.05 in the DFCI data set. We
assigned weights for these 23 genes by the signs of correlation
coefficients between each gene and the IHC based ER status, +1
or 21, and defined this as an ER expression signature. When
predicting a given microarray data set, we took the expression
profile of the 23 genes, determined their cut-off values based on
the bimodal distribution in the data set and compared the
weighted expression level of the 23 genes to the cut-off values. If 12
or more genes exceed the pre-defined cut-off values the sample
was then classified as ER positive and ER negative if 11 or fewer
genes exceeded the pre-defined cut-off values.
Survival analysis
We first performed meta-analyses in the subsets of the four
reference cohorts (EMC, JBI1, GIS, NKI) which received no
chemotherapy or endocrine therapy for IHC-based and expres-
sion-based ER statuses. Then with same method we assessed the
prognostic power of MKI67 in five-year disease-free survival
within ER positive and negative tumours in the four untreated
reference cohorts based on the IHC-based and expression-based
ER classifiers. In order to assess the clinical relevance of
misclassified ER positive or ER negative samples, we combined
the ER calls in the four reference cohorts and estimated the
hazard-ratios of expression-based ER status within IHC-based ER
positive and ER negative subsets, respectively. In order to assess
prognostic relevance in tamoxifen treated cohorts, we combined
three reference cohorts (JBI1, TAM and VDX) in which patients
were classified as IHC ER positive and all received endocrine
therapy (Tamoxifen). We estimated the hazard-ratio for ESR1-
based and signature-based ER status, respectively.
Results
An ER classifier based on ESR1 expression level
The expression profiles of many of the known breast cancer
gene markers such as ESR1, ERBB2 and AR have been shown to
follow a strong bimodal distribution, which corresponds to
different tumour subtypes[11,25,26]. Previous studies have
demonstrated that bimodal distribution of gene expression can
be used to stratify breast cancers into subtypes of distinct
prognoses and associated to known pathological risk-covariates
[27,28]. Two important issues remain to be addressed system-
atically: firstly, how can bimodality and a corresponding optimal
threshold be quantitatively defined, to select gene markers from
expression profiles enabling patient stratification; secondly, how
c a nt h ef a l s en e g a t i v er a t eb ed e f ined and minimised using these
techniques and what is its resultant impact upon clinical
outcome?
To resolve these questions, we have examined the distribution of
the ESR1 gene in ten datasets (Table 1). In nine datasets
containing both IHC-based ER positive and ER negative tumours,
we observed a bimodal distribution of ESR1 expression, with
coefficients of bimodality ranging from 0.619 to 0.776, whereas in
the data set with only IHC ER negative tumours (JBI2) there was
no visible bimodal distribution of ESR1 (coefficient of bimodality
=0.412, Supplement Figure S1).
For each of the nine data sets, we used mixed Gaussian models
to decompose the density of ESR1e x p r e s s i o ni n t ot w on o r m a l
distributions and then derived a dataset-specific, optimal
threshold value by Mahalanobis distance-based discrimination
(Supplement Figure S2 showing the distribution of ESR1 levels
for the DFCI cohort, other data not shown). We compared the
predicted ER status based on thresholding for ESR1 expression
value to the annotated ER status based on IHC for the ten data
sets and found that the two methods generated significantly
concordant classification of ER status (90.7%, Fisher exact test
P,2.20E-16, Table 2).
Table 2. Comparison of ER status determined by microarray-based classifiers to the ER status based on conventional IHC method
in 1846 samples from 10 published data sets.
Expression-based ER status ESR1 based ER+ ESR1 based ER- P value
23-gene signature
based ER+
23-gene signature
based ER- P value
IHC ER+ 93.0% 7.0% ,2.20E-16 90.9% 9.1% ,2.20E-16
IHC ER- 15.1% 84.9% ,2.20E-16 21.8% 78.2% ,2.20E-16
Overall concordance 90.7% 87.3%
Basal 7.2% 92.8% ,2.20E-16 3.9% 96.1% ,2.20E-16
Luminal A 99.8% 0.2% ,2.20E-16 98.6% 1.4% ,2.20E-16
Luminal B 99.4% 0.6% ,2.20E-16 96.3% 3.7% ,2.20E-16
Her2 36.3% 63.7% ,2.20E-16 48.7% 51.3% ,2.20E-16
doi:10.1371/journal.pone.0015031.t002
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Relying exclusively on the expression of a single gene (ESR1) or
genes which are co-regulated with ESR1 may have at least three
limitations. Firstly, the measurement of any single gene transcript can
be corrupted by experimental artefacts such as cross hybridization of
microarray probes[29]. Secondly, the detection of ESR1 transcripts
does not necessarily indicate a fully functional ER protein or ER
signalling pathway; and finally, epithelial cell ER expression status is
transient rather than constant, therefore determining ER status by its
expression in a relatively small subset of cells may introduce
additional bias[30]. Instead, the identification of genes following a
bimodal distribution, reflecting ESR1 expression in breast cancer
cohorts, which are epithelial-compartment specific, may present a
more robust strategy to develop an ER classifier.
Since ESR1 is only expressed in a proportion of epithelial cells,
the identification of epithelial-specific genes is a prerequisite to
define ER associated genes and a specific ER classifier. Therefore
we first identified a list of genes that are expressed in a wide variety
of breast cancer epithelial cell lines and tumour epithelial cells but
not in cells usually associated with breast stroma, such as
adipocytes, fibroblasts or lymphocytes. Since ESR1 alone may
not be the only component which determines the status of the
entire signalling pathway and may be subject to random effects, we
further hypothesized that genes in an ER status dependent
‘‘signature’’ will show a similar tendency to bimodality. Therefore,
we performed an exhaustive search of the entire epithelial gene list
to identify a cohort of genes with independent bimodal
distribution, of which ESR1 is also a member.
We started with a set of 17256 genes with ‘‘present calls’’ in
epithelial cell lines and enriched breast cancer epithelial cells. To
improve the specificity of these genes, we eliminated 1142 genes
which were found to be significantly over-expressed in tumour
stromal cells relative to epithelial cells from microdissected
biopsies[31]. Then we verified the bimodal distribution of these
genes in the DFCI data set using standard deviation and
coefficient of bimodality. Through this approach, we identified
258 genes for which the standard deviation across the samples is
larger than 1 and the coefficient of bimodality is larger than
0.555[32]. These 258 genes included several epithelial markers
such as KRT16, KRT23, KRT86 and MUC1 as well as several
genes related to proliferation and the cell cycle, such as CDC20,
CCNE2, CENPA, FOXA1 and FOXC1 (Figure 1).
To maximize discriminative power, we next estimated the false
positive rate (FPR) and false negative rate (FNR) for each of the 258
genes based on their binary expression status determined by the
bimodal distribution and the optimal threshold value, in the DFCI
data set (Supplement Text S1). This filtering step yielded 23 genes
with both FPR and FNR below 0.05. When combined into an ER
status-associated gene expression signature, the weights of each gene
were set to equal the sign of the correlation coefficient between the
expression level of each individual gene and that of ESR1 expression.
To validate the epithelial-specific gene selection approach and to
confirm that the correlation of the 23 genes with ESR1 expression is
unique to the epithelial gene list, we performed a similar procedure
for bimodal expression of non-epithelial genes, the resulting gene list
had a significantly lower correlation to IHC-based ER status in
comparison to our 23 gene signature (Supplement Figure S3).
Concordance between gene expression based ER
classification and IHC based ER status
Using these approaches, we have developed two gene
expression-based classifiers for ER status, the first was derived
from the expression of ESR1 and the second was derived from a
set of 23 genes specifically expressed within epithelial cells that
were selected based on their bimodal distribution. We compared
the ER status determined by these two classifiers to those based on
IHC in the ten data sets. We found that both classifiers yielded
highly concordant classifications with IHC-based ER status
(Table 2). The classifier based on ESR1 expression level was
concordant with IHC based ER status in 90.7% of the cases, and
the classifier based on the 23-gene ER signature in 87.3% of the
cases. On the other hand, both expression-based ER classification
methods produced a notable level of discrepancy with IHC-based
ER status; 9.3% and 12.7% of the samples are classified
discordantly by ESR1 and 23-gene expression-based classifiers,
respectively, compared to IHC-based ER status.
We also compared our two gene expression-based ER classifiers
to the expression profiling-based classes of Perou et al[7]. As
Figure 1. Schematic of deriving the 23-gene ER signature from
epithelial specifically expressed genes.
doi:10.1371/journal.pone.0015031.g001
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expression classification methods showed overlap with the basal-
like subtype of breast cancer (92.8%–96.1%). Moreover, expres-
sion-based ER positive tumours are significantly enriched for
luminal A (98.6%–99.8%) and luminal B (96.3%–99.4%) subtypes
(Table 2).
Gene expression-based ER status classification as a
prognostic tool
Since both IHC-based and expression-based ER classifiers may
produce false predictions due to possible technical limitations, an
evaluation of each classification method can be performed based
on their association with clinical outcome. We performed a meta-
analysis for ER status determined by IHC and by expression-based
classifiers in four publicly available data sets including patients
with both ER positive and ER negative breast cancer who received
no hormone or adjuvant chemotherapy. Since the hazard ratio
associated with ER status is time-dependent, we confined our
analysis to a maximum follow up time of 2 years in which ER
negative status is associated with a significantly higher clinical risk
than ER positive status, especially when adjuvant chemotherapy is
not implemented[33].
ER negative tumours are associated with worse clinical outcome
compared to ER positive disease. Accurate estimate of the hazard
ratio between ER negative tumours and ER positive tumours
remains difficult to estimate due to the potential for misclassifi-
cation by different classifiers. However, if the discordance in
expression-based ER classification is due to real biological
differences, the corresponding hazard ratio should be statistically
significant compared to hazard ratios estimated from random
flipping of original IHC ER calls. Our meta-analysis based on
bootstrapping four reference data sets suggested that this is indeed
the case. Both gene-expression-based ER classifications yielded
higher hazard ratios in ER negative compared to ER positive
tumours than IHC based ER status when assessing risk of disease
recurrence (disease-free survival) (IHC based ER status HR=1.84,
95% CI: 1.16–2.93, Figure 2a; ESR1 based: HR=1.98, 95% CI:
1.26–3.12, Figure 2b; 23-gene ER signature based: HR=2.31,
95% CI: 1.47–3.63, Figure 2c). The improved prognostic power
by the 23-gene signature-based ER classification was significant
based on the distribution of hazard ratios resulting from random
re-sampling of the reference data sets (P=0.006), but the one by
ESR1 expression-based ER status was not (P=0.053).
Another important clinical feature specific to ER status is the
prognostic power associated with markers of proliferation which
prognosticate in ER positive tumours but not in ER negative
tumours [10]. Therefore an ideal ER classification system should
maximize the difference between hazard-ratios for proliferation
between ER positive and ER negative tumours. To assess this we
performed a meta-analysis of the four reference cohorts for the
prognostic power of proliferation in five-year disease-free survival.
We estimated the hazard ratios of MKI67 expression, as a
surrogate index of proliferation, in ER positive and ER negative
subsets of the cohorts separately, based on both IHC-based and
expression based ER classification. The hazard ratios of MKI67
expression are consistently higher in both ESR1 expression-based
(HR=3.45, 95% CI: 2.08–5.73) and 23-gene signature based ER
positive tumours) (HR=3.99, 95% CI: 2.31–6.89) compared to
IHC-based ER positive tumours (HR=2.33, 95% CI: 1.48–3.68)
(Supplement Table S1); Bootstrapping results suggested that the
improved prognostic power of MKI67 was significant for both
ESR1-expression defined ER positive tumours (P,0.001) and for
the 23-gene expression signature defined ER positive tumours
(P,0.001). In ER negative tumours however, regardless of the
classifiers applied, MKI67 manifested no significant prognostic
power. To verify that the ER status-dependent prognostic power
of proliferation is not affected by bias in tumour stage, we
combined the ER calls in the four reference cohorts and
performed a multivariate Cox regression based on lymph-node
status, ER status, MKI67 expression and their interaction. The
results were highly consistent with our previous analyses; ER
negative status and MKI67 expression each holds independent,
significant prognostic power in five-year disease-free survival, as
well as the interaction between the two, which corresponds to the
dependence of the prognostic power of MKI67 on ER receptor
status. Moreover, the estimated hazard ratios of ER negative
Figure 2. Prognostic power of IHC-based and expression-based ER status. Meta-analysis in four cohorts suggests that ER-statuses based on
expression profile indicates stronger prognostic power than IHC based ER-status. The hazard ratios were estimated based on ER status determined by
IHC (a.), ESR1 expression (b.) and 23-gene signature (c.), separately.
doi:10.1371/journal.pone.0015031.g002
A 23 Gene Expression Signature of ER Status
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15031status, MKI67 expression and their interaction are consistently
higher when expression-based ER status is used compared to IHC-
based ER status (Table 3).
Minimising False Negative ER classification using
complementary ER status expression-based classifiers
Data presented here indicate a discrepancy between expression-
based and IHC-based ER classifiers that affects between 9.3% and
12.7% of patients (Table 2). In order to assess the clinical impact of
this potential false negative IHC discrepancy on clinical outcome,
we compared disease-free survival in this subset of patients defined
by expression-based or IHC-based ER status. Patients stratified
with IHC-based ER negative disease but with 23 gene ER
signature-based ER positive disease, had a significantly better
outcome than those that were ER negative by both methods
(Figure 3a, b). Next we assessed the outcome of patients classified
as ER positive by IHC but as ER negative by expression-based
classifiers. Patients stratified with IHC-based ER positive disease
but 23 gene ER signature-based ER negative disease had a
significantly worse outcome than their counterparts with matching
IHC and 23-gene signature based ER positive status (Figure 3c, d).
These results, together with the previous survival analyses, support
the occurrence of false positive and negative ER status
classification by IHC, which may be more efficiently classified
with respect to prognosis using the 23-gene ER expression
signature.
Gene expression based ER status classification is
associated with breast cancer outcome in patients that
received tamoxifen treatment
An important clinical implication of ER status is the benefit
patients derive from endocrine therapies such as tamoxifen. Given
the discrepancy between IHC-based ER status and expression-
based ER status, we reasoned that some of the variation seen in
the clinical benefit from tamoxifen treatment may be partially
attributable to true ER negative tumours being misclassified as ER
positive. To test this, we collected three cohorts of IHC-defined
ER positive patients with a total of 458 patients who had also
received tamoxifen. We examined the ability of our expression-
based classifiers to define outcome in these cohorts by meta-
analysis and KM curves.
In the meta-analysis of IHC-defined ER positive patients, whilst
ESR1 based ER classification was not associated with significant
higher risk of relapse (HR=1.39, 95% CI: 0.86–2.23), 23-gene
signature-based ER negative tumours within this cohort were
correlated with a poorer distant-metastasis-free survival over 5
years relative to the ER positive tumours defined by both IHC and
the 23-gene signature (HR=1.98, 95% CI: 1.19–3.28) (Supple-
ment figure S4). KM curves combining all three cohorts suggested
the same tendency, where 23-gene signature-based ER negative
but IHC based ER positive tumours were associated with a poorer
clinical outcome compared to ER positive tumours predicted by
both methods (HR=2.20, 95% CI: 1.40–3.30, P=0.00035)
(Figure 4b). Therefore ER status defined by the 23-gene signature
may identify IHC ER positive tumours at higher risk of relapse
following tamoxifen therapy. Taken together, these data suggest
that expression-based ER status classifiers identifies clinically
relevant associations with patient outcome both with and without
endocrine therapy in those patients with discrepancy between
immunohistochemistry and gene expression-based ER classifica-
tion methods.
Discussion
Improving the molecular classification of tumours with respect
to predictive or prognostic biomarkers is essential for appropriate
stratified and personalised medical approaches. False ER positive
or false ER negative calls will result in futile or insufficient therapy
for patients subject to tumour misclassfication. Given the
substantial benefit of adjuvant endocrine therapies in ER positive
disease, strategies to minimise the false negative ER status call rate
are of paramount importance to prevent patients being denied
such effective therapy[34]. Therefore, it is important to consider
additional classification methods that might contribute to
improving the reliability of ER testing in parallel with immuno-
histochemistry. Here we have presented one such approach that
relies on the expression of a group of rationally selected, ER status
associated genes. The implications of this work are that in these
historical retrospective cohorts between 15.1% and 21.8% patients
of IHC-based negative ER status would be classified with ER
positive breast cancer using expression-based methods. It is likely
that with improvements in contemporary ER assessment protocols
and standardised immunohistochemistry procedures that this
represents a significant over-estimation of the true false negative
rate.
We are not suggesting that our method should replace
traditional ER classification techniques, nor that this expression-
based should be considered for re-stratifying IHC-defined ER
positive disease as ER negative. Instead we suggest that expression-
based methods should be considered for prospective assessment as
a strategy, complementary to IHC, to minimise the potential for
Table 3. Multivariate Cox regression of lymph node status, ER status, proliferation (MKI67) and their interaction in four reference
cohorts with regard to IHC-based, ESR1-expression based and 23-gene signature based ER status.
ER classification
IHC-based ER
(N=995) ESR1 expression based (N=1004) 23-gene signature based (N=1004)
LN positive 0.98 (0.73–1.31)
P=0.87
0.97 (0.72–1.29)
P=0.82
0.96 (0.72–1.29)
P=0.79
ER negative 1.67 (1.25–2.24)
P=0.00059
1.78 (1.36–2.35)
P=5.11E-5
1.98 (1.51–2.61)
P=9.05E-7
MKI67 expression 2.76 (1.76–4.06)
P=2.82E-7
3.35 (2.15–5.23)
P=9.80E-8
3.58 (2.25–5.70)
P=7.94E-8
ER-:MKI67 interaction 0.32 (0.16–0.63)
P=0.0011
0.24 (0.12–0.47)
P=2.80E-5
0.20 (0.10–0.39)
P=3.47E-6
LN: lymph node status.
doi:10.1371/journal.pone.0015031.t003
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investigate the potential benefit of tamoxifen in patients with ER
IHC negative breast cancer whose disease is classified as ER
positive by the 23-gene ER signature.
One of the major advantages of IHC-based ER status
determination is that false negative ER calls, due to stromal
contamination and the lack of cancer cells in the material
examined, can be minimized[35,36,37]. In an attempt to minimise
the risk of false negative ER calls from our gene signature methods
due to stromal contamination, we have taken advantage of the fact
that in ER negative tumours, not only is the set of ER regulated
genes down-regulated but a well defined set of epithelial genes,
such as FOXC1 and GABRP are overexpressed as well.
Therefore, the combined set of genes that correlate and
anticorrelate with ER status may provide a reliable way of
determining ER status in tumour cells whilst minimizing the risk of
false negative calls due to excessive stromal contamination. In
order to further reduce the risk of false ER calls by the 23-gene
test, metagenes specifically measuring different tissue types could
be used to correct for bias caused by other contaminations in the
tumour samples[28].
The utility of PCR based multigenic outcome predictors has
been demonstrated previously[38]. When considering practical
realization it is important to note that the number of genes used in
our ER status classifier is comparable to that used, for example,
in the case of Oncotype recurrence score[38]. Therefore, if
Figure 3. Expression-based ER classifiers reveal misclassification of IHC-based ER status which associated with clinical outcome. KM
curves of disease-free survival showing IHC based ER- tumours separated by (a.) ESR1 expression-based and (b) 23-gene signature-based ER status;
false ER- (23-gene signature based ER+, IHC based ER-) showed significantly better outcome which is close to true ER+ (23-gene signature based ER+,
IHC based ER+, black dashed-line). And IHC based ER- tumours are separated by (c.) ESR1 expression and (d.) 23-gene signature based ER status; false
ER+ (23-gene based ER-, IHC based ER+) showed significantly worse outcome which is close to true ER- (23-gene signature based ER-, IHC based ER-,
red dashed-line).
doi:10.1371/journal.pone.0015031.g003
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15031prospective studies of this multigene predictor in combination with
IHC determine clinical utility that is complementary with IHC-
based classification methods, it is reasonable to expect that this
gene expression based method, especially in the case of
questionable cases, may be added to the histopathological and
molecular classification of breast cancer. We are currently
planning to prospectively evaluate the benefit of such a test to
minimise immunohistochemistry-defined false negative oestrogen
receptor status classification.
Conclusions
We have demonstrated that ER expression status determined
from microarray data enables more accurate determination of
clinical outcome of breast cancer in multiple reference cohorts.
Our methods provided a set of gene markers which stratify breast
cancer in terms of hormone receptor expression status and may
further help to understand the biological background of hetero-
geneity of breast cancer. Moreover, with this 23-gene signature
based ER classification method we have distinguished a subset of
IHC ER positive breast cancer patients that have a poorer
outcome following endocrine therapy that may be attributable to
false positive classification of ER status by current histopatholog-
ical methods. With future efforts, our approach may provide a new
multi-gene assay to improve clinical stratification of hormone
receptor positive breast cancer.
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Figure S1 Verification of bimodal distribution of ESR1
mRNA expression. a. DFCI; b. MSK; c. MDA1; d. MDA/
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Figure S2 Bimodal distribution of ESR1 is associated
with IHC ER status. ESR1 (‘‘205225_at’’) expression levels
follow a bimodal distribution in DFCI data set (left) and the
inferred cutoff value based on the bimodal distribution is highly
consistent with ER status determined by IHC (right).
(EPS)
Figure S3 Epithelial genes with bimodal distribution
indicated higher correlation to IHC-based ER status.
(EPS)
Figure S4 23-gene signature based ER status is associ-
ated with clinical outcome of tamoxifen-treated breast
cancers. Meta-analysis in three cohorts suggests that ER-statuses
based on 23-gene expression signature indicate stronger predictive
power than IHC based ER-status. The hazard ratios were
estimated based on ER status determined by (a.) ESR1 expression
and (b.) 23-gene ER signature, separately.
(EPS)
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the prognostic power of proliferation (MKI67) within ER
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